Header Logo

RFH Newsletter

Home / News and Features / Thoracic Malignancies

By Dr. Marzi Mehta,


1. Diagnostic evaluation of non-small lung cancer:

  • History and physical examination
  • ECOG scoring (performance index evaluation)
  • PET with contrast enhanced CT thorax (with special reference to thorax and upper abdomen to include adrenals)
  • Bronchoscopy: for central tumours along with bal and brushings
  • CT guided trucut biopsy for peripheral tumours or tumours not amenable to bronchoscopic biopsy
  • Ebus / mediastinoscopy: it is extremely vital to stage the mediastinum prior to surgery. The test needs to be done only for operable cases
  • Pulmonary function test with DLCO.

2. Treatment of non-small cell lung cancer:

a. Early localized:

  • Stage I NSCLC: treatment is surgery (lobectomy). This is to be done if the patient has enough respiratory reserve, i.e. expected post-operative FEV1 should be >0.8 or 40% and post-operative DLCO should be >0.8 or 40%.The Lobectomy is performed either through the conventional Thoracotomy or via VATS (Video Assisted Thoracoscopic Surgery).
  • Stage II NSCLC: surgery (conventional Thoracotomy or via VATS (Video Assisted Thoracoscopic Surgery) as for stage 1. no adjuvant therapy.

b. Locally Advanced Resectable: Stage IIIA: (T3 N1 Mx) : (T1-3 N2 Mx):

  • T3 N1: will be treated with neoadjuvant chemotherapy consisting of two cycles of chemotherapy followed by surgical resection. Adjuvant radiation in case of positive margins.
  • N2 Disease: Patients with good performance status, no contra-indication to surgery are to be treated with neoadjuvant chemotherapy for 2 cycles followed by surgery. If patient’s have low performance status or contra-indication to surgery, but have adequate pulmonary function tests then definitive chemo- radiotherapy can be done, otherwise palliative radiotherapy.


c. Locally Advanced Unresectable:

  • Patients with good performance status 0-2 and good pulmonary function tests should have combined modality therapy. The patients will receive concurrent chemotradiotherapy (both starting on day 1).
  • Patients’ poor performance status 3-4 and/or poor pulmonary function test should receive palliative radiotherapy.
  • Metastatic non-small cell lung cancer: treatment is palliative and prognosis poor. Newer targeted agents such as Gefitinib/ Afatinib for EGFR Positive, Crizotinib for ALK Positive and Nivolumab for anti-PD-1 monoclonal antibody may improve the overall survival in a select group of patients. Recurrent pleural effusion: May be subjected to a VATS Pleurodesis (Fig 4) or Pleurx catheter insertion.


1. Non Invasive Thymoma:
Surgical resection via Sternotomy or VATS Mediastinal mass resection (ENBLOC).

2. Invasive Thymoma: Stage 1:
Surgical resection as described above. Radiation therapy only if incompletely resected or poor surgical risk.

3. Stage II, III, IV:

  • Operable cases: en block resection neither through midline sternotomy or VATS with post-operative radiotherapy if positive margin.
  • Inoperable cases: like Stage III and IV will be treated with three cycles of neoadjuvant chemotherapy followed by radiation therapy and then surgical resection of residual disease if possible.

Esophageal Malignancy




Google Play Icon
Get it onGoogle Play
App Store Icon
Download on theApp Store
  • Facebook Icon
  • X Icon
  • Youtube Icon
  • Instagram Icon

© 2023 Sir H. N. Reliance Foundation Hospital and Research Centre